Media stories about Zoetis (NYSE:ZTS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.6351970701934 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Zoetis Inc. (ZTS) projected to achieve 32.40% earnings growth for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Roman Trawicki Sells 8,568 Shares of Zoetis Inc (ZTS) Stock (americanbankingnews.com)
- Zoetis Inc. (ZTS) Stock Unusual Activity – Wall Street Morning (wallstreetmorning.com)
- Zoetis Inc (ZTS) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
Several brokerages have recently issued reports on ZTS. Cowen set a $80.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, November 17th. UBS Group reiterated a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research note on Wednesday, November 29th. Cantor Fitzgerald set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $85.00 price target (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $80.28.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the company posted $0.47 EPS. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. analysts predict that Zoetis will post 3.04 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. Zoetis’s dividend payout ratio (DPR) is 28.57%.
In other news, insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares of the company’s stock, valued at $4,044,437.38. The disclosure for this sale can be found here. Insiders sold a total of 105,569 shares of company stock valued at $8,594,429 over the last quarter. Company insiders own 0.31% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://baseballnewssource.com/2018/03/14/zoetis-zts-getting-somewhat-favorable-news-coverage-study-finds/1889539.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.